Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections

Keyphrases

• Antifungal Agents 33%
• Antifungal Drugs 33%
• Antifungal Prophylaxis 33%
• Antifungal Susceptibility 33%
• Antifungal Therapy 66%
• Armamentarium 33%
• Clinical Presentation 33%
• Clinical Trials 33%
• Cross-resistance 33%
• Diagnostic Modalities 33%
• Difficult-to-treat 100%
• Difficult-to-treat Infections 33%
• Disease Manifestations 33%
• Drug Interactions 33%
• Early Detection 33%
• Epidemiology 33%
• Fosmanogepix 33%
• High Mortality 33%
• Host Immune Response 33%
• Immunocompromised Patients 33%
• Immunomodulatory 33%
• Invasive Fungal Disease 66%
• Knowledge Gaps 33%
• Lomentospora Prolificans 33%
• Lomentosporiosis 100%
• Modern Perspective 100%
• Mold Infection 100%
• Molecular Agents 33%
• New Antifungal 33%
• New Antifungal Agents 33%
• Novel Mechanism of Action 33%
• Olorofim 33%
• Oral Administration 33%
• Pediatric Setting 33%
• Rare Moulds 100%
• Recent Advances 33%
• Scedosporiosis 100%
• Scedosporium 66%
• Uncommon Causes 33%

Medicine and Dentistry

• Antifungal Agent 60%
• Antifungal Susceptibility 20%
• Antifungal Therapy 40%
• Clinical Trial 20%
• Cohort Effect 20%
• Cross Resistance 20%
• Diseases 20%
• Drug Interaction 20%
• Fungal Infection 40%
• Immune Response 20%
• Immunocompromised Patient 20%
• Infection 100%
• Olorofim 20%
• Oral Drug Administration 20%
• Pediatrics 20%
• Pseudallescheriasis 100%